Bifidobacterium

Bifidobacteria belong to the phylum Actinobacteria, class Actinomycetes, order Bifidobacteriales, and family Bifidobacteriaceae. The genus was first described in 1899 by Henri Tissier, who isolated it from the feces of breastfed infants and named it Bacillus bifidus due to its characteristic bifurcated morphology. Later, in 1924, Orla-Jensen reclassified it into the genus Bifidobacterium. Phylogenetically, bifidobacteria are distinct from lactic acid bacteria, although they share ecological niches and are often grouped with them in probiotic contexts. The genus comprises over 90 recognized species, with B. bifidum, B. longum, B. breve, and B. adolescentis being the most studied. Comparative genomics has revealed a high degree of genetic diversity, with genome sizes ranging from 1.9 to 3.5 Mb, reflecting adaptation to various ecological niches, including the gut, oral cavity, and even sewage.

Bifidobacteria are saccharolytic anaerobes that ferment carbohydrates to produce acetic and lactic acids via the unique bifid shunt pathway, which uses the enzyme fructose-6-phosphate phosphoketolase (F6PPK). This pathway yields a 3:2 molar ratio of acetate to lactate, which lowers the intestinal pH and inhibits pathogenic bacteria. They possess a wide array of carbohydrate-active enzymes, including glycoside hydrolases that break down complex plant polysaccharides and host-derived glycans, such as mucin. Some species, like B. bifidum, can utilize human milk oligosaccharides (HMOs), a trait that explains their dominance in breastfed infants. Bifidobacteria also produce vitamins, particularly B-group vitamins, and exhibit bile salt hydrolase activity, which aids in lipid metabolism. Their metabolic versatility is a key factor in their probiotic efficacy and their ability to colonize different gut environments.

Bifidobacteria are among the most widely used probiotics, with clinical evidence supporting their role in alleviating irritable bowel syndrome, preventing antibiotic-associated diarrhea, and reducing the incidence of necrotizing enterocolitis in preterm infants. They modulate the host immune system by interacting with dendritic cells and promoting regulatory T-cell responses, thereby reducing inflammation. Specific strains, such as B. longum subsp. longum 35624, have been shown to improve quality of life in patients with ulcerative colitis. Additionally, bifidobacteria may influence the gut–brain axis, with some studies suggesting a role in reducing anxiety and depressive symptoms. However, clinical outcomes are strain-specific, and not all species exhibit the same benefits. The mechanisms include production of short-chain fatty acids, competitive exclusion of pathogens, and enhancement of intestinal barrier integrity.

Beyond the gut, bifidobacteria have been isolated from the oral cavity, vagina, and even from the feces of insects and birds, indicating a broader ecological distribution. Some species, such as B. minimum and B. subtile, are found in sewage and anaerobic digesters, where they contribute to organic matter degradation. Bifidobacteria are also used in the food industry not only as probiotics but also as starter cultures for fermented dairy products, and their enzymes are employed in the synthesis of galacto-oligosaccharides (GOS), which are prebiotic ingredients. A notable historical fact is that the first complete genome sequence of a bifidobacterium, B. longum NCC2705, was published in 2002, revealing its genetic adaptations to the gut environment. Additionally, bifidobacteria have been detected in ancient human fecal samples, suggesting a long co-evolutionary history with humans. Research is ongoing into their potential role in modulating the gut microbiome in aging populations and in conditions like autism spectrum disorder.

Probiotic

Live microorganisms that confer health benefits when administered in adequate amounts.

Prebiotic

Non-digestible food ingredients that stimulate the growth of beneficial microorganisms.

Human milk oligosaccharides

Complex carbohydrates in breast milk that selectively promote the growth of bifidobacteria.

Bifid shunt

A unique metabolic pathway in bifidobacteria that produces acetate and lactate from carbohydrates.